Tech Company Financing Transactions
Juventas Therapeutics Funding Round
Juventas Therapeutics closed a $13.5 million funding round on 5/12/2015. Investors included Green Cross Holdings, POSCO Venture Capital and Oxford Finance.
Transaction Overview
Company Name
Announced On
5/12/2015
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$13,500,000
Round
Undisclosed
Investors
Proceeds Purpose
We have made significant progress and this financing allows us to lay the groundwork for the initiation of multiple Phase 2b clinical studies. Our upcoming studies will evaluate JVS-100 for the treatment of patients with chronic heart failure and late stage peripheral artery disease, two indications with limited therapeutic options.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3615 Superior Ave. 4403B
Cleveland, OH 44114
USA
Cleveland, OH 44114
USA
Phone
Website
Email Address
Overview
Juventas Therapeutics is a privately held biotechnology company developing a pipeline of regenerative therapies to treat life--threatening diseases. The company's lead product, Stromal--cell Derived Factor 1 (SDF--1), has been shown to protect and repair tissue following organ--damage in a broad range of pre--clinical disease models.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rahul Aras
Chief Medical Officer
Matthew Pollman
VP - Operations
Michael Fitzgerald
VP - Product Management
Joseph Pastore
Browse more venture capital transactions:
Prev: 5/12/2015: ScaleFT venture capital transaction
Next: 5/12/2015: NerdWallet venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs